Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 06, 2026 16:15 ET | Source: ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

PRINCETON, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the...
January 06, 2026 10:05 ET | Source: SNS Insider pvt ltd

Vision Care Market Size to Hit USD 246.89 Billion by 2033, Growing at a CAGR of 6.75% - SNS Insider

Austin, Texas, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vision Care Market Size & Growth Analysis: According to SNS Insider, The Vision Care Market size was valued at USD 146.58 billion in 2025 and is...
January 06, 2026 08:00 ET | Source: SpyGlass Pharma, Inc.

SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer

ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a late-stage biopharmaceutical company, today announced the appointment of Jean-Frédéric Viret, Ph.D., as the company’s Chief...
January 06, 2026 07:26 ET | Source: Biocon Biologics Ltd

Biocon Biologics to Expand Biosimilar Oncology Portfolio, Outline Strategic Vision at the 2026 J.P. Morgan Healthcare Conference

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of...
January 06, 2026 04:00 ET | Source: Oculis Holding AG

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis

ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritisPrivosegtor is advancing...
January 06, 2026 04:00 ET | Source: Oculis Holding AG

Oculis tilkynnir um að Matvæla- og lyfjastofnun Bandaríkjanna (FDA) hafi veitt Privosegtor stöðu byltingarkennds meðferðarlyfs til meðhöndlunar á sjóntaugabólgu

ZUG, Sviss, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Taugaverndandi þróunarlyfið Privosegtor hefur fengið stöðu byltingarkennds meðferðarlyfs (e. Breakthrough Therapy Designation) til meðhöndlunar á...
January 06, 2026 04:00 ET | Source: Oculis Holding AG

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis

ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is...
January 05, 2026 10:00 ET | Source: SNS Insider pvt ltd

G-Protein Coupled Receptors (GPCRs) Market Size to Hit USD 6.04 Billion by 2032, Growing at a CAGR of 5.59% - SNS Insider

Austin, Texas, Jan. 05, 2026 (GLOBE NEWSWIRE) -- G-Protein Coupled Receptors (GPCRs) Market Size & Growth Analysis: According to SNS Insider, The G-protein coupled receptors (GPCRs) market...
January 05, 2026 09:00 ET | Source: YD Bio Limited

YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap

Taipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and...
January 05, 2026 08:05 ET | Source: Kriya Therapeutics, Inc.

Kriya Appoints Sachiyo Minegishi as Chief Financial Officer

RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. (“Kriya”), a clinical-stage biopharmaceutical company developing life-changing gene therapies for conditions...